• M M Rabiei, K S Khoramgah, I A Darazam, S Vafaei-Nezhad, S Dargahi, and H A Abbaszadeh.
• Bratisl Med J. 2021 Jan 1; 122 (11): 785-792.

ObjectivesThe present study was aimed to investigate the therapeutic effect of mesenchymal Stem Cell Therapy in the left ventricular ejection fraction (LVEF), left ventricular enddiastolic volume (LVEDV), and  left ventricular endsystolic volume (LVESV) after myocardial infarction (MI).BackgroundPrevious investigations propose that stem cell therapy may help treat myocardial infarction (MI). However, there are controversial data from different studies.MethodsWe studied the relevant scientific literature available up to 2020. Comprehensive Meta-Analysis Software (CMAS) Version 2.0 were used for statistical analyses. Fixed or random-effect model was used to identify the weighted mean difference (WMD) with 95% confidence intervals (CI). The statistically significant level used for interpreting publication bias was less than 0.05.ResultsWe identified 30 studies that met the inclusion criteria. In the overall pooled estimate, cell therapy had an effect on the LVEF change from baseline to follow-up (WMD: 2.98 mL, 95% CI: 1.66 to 4.29). The pooled WMD was found to be -4.16 (95% CI: -7.91 to -0.40) and -5.62 (95% CI: -9.20 to -2.00), for LVEDV, and LVESV, respectively. Thus, reduction in LVEDV and LVESV were significant in the treatment group participants.ConclusionsThe present systematic review indicated that cell therapy in patients, who have MI could be effective and applicable clinically (Tab. 3, Fig. 7, Ref. 48). Text in PDF www.elis.sk Keywords: myocardial infarction, stem cell, systematic review, randomized clinical trials.

7 keywords...

hide…